Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 4/20 | 1.00 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | NPY1R | P25929 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NPY2R | P49146 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gr-190178 SCHEMBL6559897 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1DNPH1LMNAALDH1A1 | |
| SCHEMBL6657691 | 0.90 | ADORA3 (0.81) | ADORA3ADORA1DNPH1LMNAALDH1A1 | |
| SCHEMBL6657697 | 0.90 | ADORA3 (0.81) | ADORA3ADORA1DNPH1LMNAALDH1A1 | |
| SCHEMBL7526882 | 0.88 | ADORA3 (0.79) | ADORA3ADORA1 | |
| SCHEMBL6559694 | 0.87 | ADORA3 (0.77) | ADORA3ADORA1DNPH1LMNAALDH1A1 | |
| SCHEMBL6559701 | 0.87 | ADORA3 (0.77) | ADORA3ADORA1DNPH1LMNAALDH1A1 | |
| SCHEMBL7526523 | 0.87 | ADORA3 (0.77) | ADORA3ADORA1 | |
| SCHEMBL7526517 | 0.87 | ADORA3 (0.77) | ADORA3ADORA1 | |
| SCHEMBL6659305 | 0.84 | ADORA1 (0.72) | ADORA3ADORA1DNPH1LMNAALDH1A1 | |
| SCHEMBL6659300 | 0.84 | ADORA1 (0.72) | ADORA3ADORA1DNPH1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167092-A1 | Medicaments | BOUNTRA CHARANJIT (GB) | 2004-08-26 | — | — | US | claimed |
| EP-1397147-A1 | USE OF ADENOSINE A1 AGONISTS IN THE TREATMENT OF EMESIS | GLAXO GROUP LIMITED (GB) | 2004-03-17 | — | — | EP | claimed |
| WO-2002069982-A1 | MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2002-09-12 | — | — | WO | claimed |
| US-20040167092-A1 | Medicaments | BOUNTRA CHARANJIT (GB) | 2004-08-26 | — | — | US | disclosed |
| EP-1397147-A1 | USE OF ADENOSINE A1 AGONISTS IN THE TREATMENT OF EMESIS | GLAXO GROUP LIMITED (GB) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002069982-A1 | MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167092-A1 | Medicaments | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA1 1/4885DNPH1 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.